Posted by Michael Wonder on 15 Nov 2022
FDA approves tremelimumab in combination with durvalumab and platinum-based chemotherapy for metastatic non-small-cell lung cancer
10 November 2022 - Today, the FDA approved tremelimumab (Imjudo, AstraZeneca) in combination with durvalumab (Imfinzi, AstraZeneca) and platinum-based chemotherapy for adult patients with metastatic non-small-cell lung cancer with no sensitising epidermal growth factor receptor mutation or anaplastic lymphoma kinase genomic tumour aberrations.
Efficacy was evaluated in POSEIDON, a randomised (1:1:1), multi-centre, active-controlled, open-label trial in patients with metastatic non-small-cell lung cancer who had not received prior systemic treatment.
